Department of Pharmacology Archives
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Dec. 7, 2017—Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan.
Nov. 16, 2017—Using sophisticated genome mining and gene manipulation techniques, researchers at Vanderbilt University Medical Center (VUMC) have solved a mystery that could lead to a new treatment approach for autism spectrum disorder (ASD).
Oct. 19, 2017—Dan Roden, M.D., Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center (VUMC), was named to receive the 2017 Medicine Alumni Global Lifetime Achievement Award by the Faculty of Medicine of his alma mater, McGill University.
Sep. 21, 2017—John Oates, M.D., a pioneering clinical pharmacologist at Vanderbilt University Medical Center (VUMC), has been awarded a one-year, $20,000 grant from the Brain Aneurysm Foundation to support studies of the stroke-reducing potential of acetaminophen.
Sep. 21, 2017—Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology.
Sep. 20, 2017—An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.